Organized by: |
SIEP, The Society for the Investigation of Early
Pregnancy
IFPA, The International Federation of Placenta Associations |
Presidents: |
Eytan R. BARNEA
Richard K. MILLER |
Embryo Maternal Dialogue:
From Pregnancy Recognition To Proliferation Control
Eytan R. Barnea, MD, FACOG
SIEP Chairman, The Society for the Investigation of Early Pregnancy
Embryo-maternal dialogue starts shortly after
fertilization and is exerted through both local and systemic signaling. We have discovered
specific embryo derived pre-implantation factors (PIF), novel peptides that are secreted
already at the two cell stage and which modulate cellular immunity. In the fallopian tube
the embryo, a partial allograft, is tolerated by the mother. Embryo derived peripheral
signaling (PIF) is also detected prior to implantation in maternal sera. This signal may
also help prime the endometrium to facilitate implantation. Upon implantation,
embryo-endometrial communication becomes direct and highly amplified. When the immune
privilege appears to be secured, embryogenesis proper initiates. This requires
proliferation / differentiation to be tightly controlled. Knowledge of proliferation
promoters is ample while the factors involved in its control remain less understood. We
have identified a class of novel proteins/peptides, developmental proteins (DPs), that are
present in the embryo before a mature immune system has developed. Their role is to create
a balance between pro and antiproliferative forces, to promote normal proliferation while
controlling abnormal cell proliferation (i.e. due to carcinogens, toxins, viruses, and
ionic radiation). DPs, may also redirect growth towards functionality through
differentiation. DPs appear to act through a specific receptor negating growth factors
action through promotion of tumor suppressors and inhibition of tumor promoters at 2
minutes, blocking DNA synthesis at ~24 hours, and promoting apoptosis at ~48 hours. When
an embryo becomes incompatible with life, DPs may lead to growth arrest, PIF-like
compounds decline, the immune system to be restored and the pregnancy is rejected.
Final identification and use of PIF and DPs is likely to help both
managing early pregnancy disorders and aid in treatment of proliferative disorders due to
cancer and viral infection.
For personal use. Only reproduce with permission
from SIEP.